<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75619">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003144</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-NMO-302</org_study_id>
    <secondary_id>2013-001151-12</secondary_id>
    <nct_id>NCT02003144</nct_id>
  </id_info>
  <brief_title>An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients</brief_title>
  <official_title>A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether eculizumab long-term use is safe and
      effective in patients with relapsing NMO.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label extension study to confirm the long term safety and efficacy of
      eculizumab in subjects with relapsing NMO who have completed the initial double-blind,
      randomized, placebo-controlled trial ECU-NMO-301.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the long-term safety of eculizumab in patients with relapsing NMO.</measure>
    <time_frame>From first dose to study completion (maximum of 4 years).</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), change from baseline in vital signs, clinical laboratory tests, and suicide risk as assessed with Columbia-Suicide Rating Scale (C-SSRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the long-term efficacy of eculizumab in patients with relapsing NMO</measure>
    <time_frame>From first dose to study completion (maximum of 4 years).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Annualized Relapsing Rate, disability, quality of life and neurologic function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in patients with relapsing NMO</measure>
    <time_frame>From first dose to study completion (maximum of 4 years).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in plasma PK of eculizumab and in free C5 activity (PD marker) before and after treatment with the study drug.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eculizumab intravenous infusion every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patient completed the ECU-NMO-301 trial

          2. Patient has given written informed consent

        Key Exclusion Criteria:

          1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related
             to trial drug

          2. Female patients who are pregnant, breastfeeding, or intend to conceive during the
             course of the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
    <email>clinicaltrials@alxn.com</email>
  </overall_contact>
  <reference>
    <citation>Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26.</citation>
    <PMID>23623397</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long-term safety study</keyword>
  <keyword>Extension trial</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
  <keyword>Devic's disease</keyword>
  <keyword>Transverse Myelitis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Relapse</keyword>
  <keyword>NMO-IgG</keyword>
  <keyword>CNS Autoimmune Disorders</keyword>
  <keyword>Demyelinating Disorders</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
